New trial for leukemia patients: HOVON 150

Treatment with ivosidenib or enasidenib for patients with mutations in enzymes (IDH1 or IDH2 mutation)

New trial for leukemia patients: HOVON 150

Treatment with ivosidenib or enasidenib for patients with mutations in enzymes (IDH1 or IDH2 mutation)

This trial is investigating whether ivosidenib and enasidenib can improve treatment outcomes in patients with newly diagnosed AML or MDS-EB2 and IDH1 or IDH2 mutation.

Adult patients (18 and above) can take part in this trial.

For more information on where and how this trial is conducted, consult the trial website. 

All News
21 January 2020